China Top 60 Biopharmaceutical Manufacturing Directory - Second Edition
DESCRIPTION
The completely updated, comprehensive Top 60 Directory provides detailed profiles of China biopharmaceutical facilities, including information on their capacity, history, products, scale, management, business focus, products, R&D, business and partnering strategies, strengths and weaknesses, and future objectives. The directory also highlights current and upcoming facilities, and includes information on key marketed and clinical trial products.
“Top 60 Biopharmaceutical Facilities in China Directory” allows readers to keep up-to-date on new and existing biopharmaceutical facilities as the industry continues to grow and expand. This newly updated directory helps you stay aware of current key participants, as well as new and upcoming facilities in this rapidly changing market.
Directory Content
This second edition of BioPlan Associates' facilities directory of major biopharmaceutical manufacturing facilities in China covers facilities with the most bioprocessing capacity (total bioreactor volumes), and those under active construction. Facility information includes:
Company ownership, background, management and facility capacity and history.
Financial estimates are provided, along with derived data regarding facility size, available partnership resources, etc.
The ranking of companies is based on facility factors including aspects such as:
Our Team in the News
Vicky Qing XIA, Sr. Project Manager.
MS Biology University of Texas, MBA University of Pittsburgh, has extensive experience in alliance management in China's bio-pharmaceutical industry; has worked with major biopharma facilities in US and China. Her expertise includes analysis of global markets; she also authors biotech publications and newsletters.
Yibing (Eliza) Zhou, Project Director, China.
Yibing Zhou manages pharmaceutical and biotechnology programs in China. She is an editor and author for “Advances in Biopharmaceutical Technology in China” by BioPlan and the Society for Industrial Microbiology. Ms. Zhou holds a Bachelor of Pharmaceutical Chemistry (1987) from the West China University of Medical Sciences (merged into Sichuan University in 2001).
The completely updated, comprehensive Top 60 Directory provides detailed profiles of China biopharmaceutical facilities, including information on their capacity, history, products, scale, management, business focus, products, R&D, business and partnering strategies, strengths and weaknesses, and future objectives. The directory also highlights current and upcoming facilities, and includes information on key marketed and clinical trial products.
“Top 60 Biopharmaceutical Facilities in China Directory” allows readers to keep up-to-date on new and existing biopharmaceutical facilities as the industry continues to grow and expand. This newly updated directory helps you stay aware of current key participants, as well as new and upcoming facilities in this rapidly changing market.
Directory Content
This second edition of BioPlan Associates' facilities directory of major biopharmaceutical manufacturing facilities in China covers facilities with the most bioprocessing capacity (total bioreactor volumes), and those under active construction. Facility information includes:
Company ownership, background, management and facility capacity and history.
Financial estimates are provided, along with derived data regarding facility size, available partnership resources, etc.
The ranking of companies is based on facility factors including aspects such as:
- Total liters' capacity
- Number of employees related to biologics production
- Number of products in commercial or clinical production.
- 357 pages
- Over 75+ Chinese-owned biopharmaceutical organizations, plus up-and-coming facilities!
- Includes recombinant and protein therapeutic biopharmaceutical companies and vaccine manufacturers
- Online China Top 60 Database
Our Team in the News
Vicky Qing XIA, Sr. Project Manager.
MS Biology University of Texas, MBA University of Pittsburgh, has extensive experience in alliance management in China's bio-pharmaceutical industry; has worked with major biopharma facilities in US and China. Her expertise includes analysis of global markets; she also authors biotech publications and newsletters.
Yibing (Eliza) Zhou, Project Director, China.
Yibing Zhou manages pharmaceutical and biotechnology programs in China. She is an editor and author for “Advances in Biopharmaceutical Technology in China” by BioPlan and the Society for Industrial Microbiology. Ms. Zhou holds a Bachelor of Pharmaceutical Chemistry (1987) from the West China University of Medical Sciences (merged into Sichuan University in 2001).
1. CHINA BIOPHARMACEUTICAL MANUFACTURING
2. STUDY METHODOLOGY
Table 1: Top 60 Biopharmaceutical Companies in China (By Ranking)
3. MAJOR EVENTS IN CHINA BIOPHARMA
Table 2: Launch Of Major Biological Products (Mostly mAb), 2006-2016
Table 3: New Mab Makers And Chemical Drug Makers Entering mAb Sector
4. SUMMARY OF CHINA BIOPHARMACEUTICAL MANUFACTURERS
Table 4: China Biopharmas by Facility Primary Manufacture Type
5. PROFILES OF 10 BIOPHARMACEUTICAL ORGANIZATIONS IN CHINA
6. APPENDIX: EMERGING BIOPHARMA COMPANIES IN CHINA
2. STUDY METHODOLOGY
Table 1: Top 60 Biopharmaceutical Companies in China (By Ranking)
3. MAJOR EVENTS IN CHINA BIOPHARMA
Table 2: Launch Of Major Biological Products (Mostly mAb), 2006-2016
Table 3: New Mab Makers And Chemical Drug Makers Entering mAb Sector
4. SUMMARY OF CHINA BIOPHARMACEUTICAL MANUFACTURERS
Table 4: China Biopharmas by Facility Primary Manufacture Type
5. PROFILES OF 10 BIOPHARMACEUTICAL ORGANIZATIONS IN CHINA
6. APPENDIX: EMERGING BIOPHARMA COMPANIES IN CHINA
